A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.

Jin, Ying; Li, Jin; Shen, Lin; Xu, Jianming; Zhang, Yanqiao; Zhang, Jingdong; Pan, Hongming; Qu, Xiujuan; Chen, Yamin; Zhang, Qiang; Li, Jinnan; Sun, Miaomiao; Qin, Shukui

Jin, Ying; Li, Jin; Shen, Lin; Xu, Jianming; Zhang, Yanqiao; Zhang, Jingdong; Pan, Hongming; Qu, Xiujuan; Chen, Yamin; Zhang, Qiang; Li, Jinnan; Sun, Miaomiao; Qin, Shukui.

Afiliação

Jin Y; Department of Medical Oncology, Sun Yat-Sen University Cancer Centre, Guangzhou, China.
Li J; Department of Medical Oncology, Shanghai Oriental Hospital Affiliated Tongji University East Hospital, Shanghai, China.
Shen L; Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China.
Xu J; Department of Medical Oncology, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China.
Zhang Y; Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.
Zhang J; Department of Gastroenterology, Liaoning Cancer Hospital and Institute, Shenyang, China.
Pan H; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Chen Y; Department of Medical Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhang Q; Eli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Li J; Eli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Sun M; Eli Lilly and Company, Lilly China Drug Development and Medical Affairs Centre, Shanghai, China.
Qin S; Department of Medical Oncology, People's Liberation Army (PLA) Cancer Centre of Jinling Hospital, Nanjing, China.

Front Oncol ; 12: 1044328, 2022.

Article em En | MEDLINE | ID: mdl-36505849

Palavras-chave

FRESCO; fruquintinib; metastatic colorectal cancer; progression free survival; real-world data; tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Colon_e_reto Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google